Repligen Corp vs. TScan Therapeutics, Inc. Common Stock
Repligen Corp (RGEN) comes out ahead, leading on 5 of 8 compared factors.
Size & Scale
| RGEN | TCRX | |
|---|---|---|
| Market Cap | $9.35 billion | $52.39 million |
| Revenue (TTM) | $785.10 million | $7.11 million |
| Net Income (TTM) | $41.54 million | $-117,712,000 |
RGEN leads on 3 of 3 size & scale factors.
Valuation
| RGEN | TCRX | |
|---|---|---|
| P/E Ratio | 228.53 | — |
| Price / Book | 4.43 | 0.76 |
| Price / Sales | 11.91 | 7.37 |
TCRX leads on 2 of 2 valuation factors.
Profitability
| RGEN | TCRX | |
|---|---|---|
| Net Margin | 5.29% | -1655.35% |
| Return on Equity | 1.97% | -170.55% |
RGEN leads on 2 of 2 profitability factors.
Risk & Sentiment
| RGEN | TCRX | |
|---|---|---|
| Short Interest | 7.13% | 0.01% |
TCRX leads on 1 of 1 risk & sentiment factors.
Dig deeper: RGEN overview, RGEN financials, TCRX overview, TCRX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.